Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
48
Recruiting, any sponsor type, condition "hemophilia"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed398
48 trials
Showing 1 to 25, recently updated first.
- A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT05611801 · 100 participants (planned) · Start Dec 9, 2022 · Primary completion Sep 10, 2028
Drug: marstacimab · For: Hemophilia A; Hemophilia B
Sites: Salt Lake City, Utah; Mendoza, Argentina; Parkville, Australia · 62 sites in all
PfizerPfizer (PFE)
NCT06703606 · 15 participants (planned) · Start May 13, 2025 · Primary completion May 5, 2027
Drug: MARSTACIMAB · For: Severe Hemophilia A
Sites: La Jolla, California; Los Angeles, California; San Diego, California · 10 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06379789 · 130 participants (planned) · Start Sep 11, 2024 · Primary completion Aug 14, 2034
Drug: REGV131; LNP1265 · For: Hemophilia B
Sites: Phoenix, Arizona; Los Angeles, California; Sacramento, California · 54 sites in all
- A Study to Learn About the Study Medicine (Called Marstacimab) in People With Hemophilia A or BRecruiting
PfizerPfizer (PFE)
NCT07859527 · 100 participants (planned) · Start Nov 16, 2026 · Primary completion Aug 30, 2028
Drug: Marstacimab · For: Hemophilia
Sites: New York, New York
OctapharmaIndustry
NCT05936580 · 28 participants (planned) · Start May 12, 2026 · Primary completion Feb 2027
Drug: Nuwiq · For: Hemophilia A
Sites: San Antonio, Texas; Helsinki, Finland; Chambray-lès-Tours, France · 17 sites in all
OctapharmaIndustry
NCT05935358 · 28 participants (planned) · Start Nov 28, 2023 · Primary completion Dec 2026
Drug: Nuwiq · For: Severe Hemophilia A
Sites: Dallas, Texas; Zagreb, Croatia; Helsinki, Finland · 18 sites in all
BayerBayer (BAYRY)
NCT07088458 · 40 participants (planned) · Start Jul 16, 2026 · Primary completion Dec 31, 2029
Drug: Damoctocog alfa pegol (Jivi, Bay94-9027) · For: Hemophilia A
Sites: Loma Linda, California; New Brunswick, New Jersey; Many Locations, Brazil · 12 sites in all
- Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and ChildrenPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07838194 · 50 participants (planned) · Start Nov 30, 2026 · Primary completion Sep 30, 2028
Drug: NXT007 · For: Hemophilia A
Sites: Kawasaki-Shi, Japan
TakedaTakeda (TAK)
NCT06550882 · 11 participants (planned) · Start Jul 22, 2025 · Primary completion Dec 31, 2028
Drug: OBIZUR · For: Acquired Hemophilia A
Sites: Seoul, South Korea; Ulsan, South Korea · 4 sites in all
- A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia ARecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07226206 · 5 participants (planned) · Start Sep 8, 2026 · Primary completion Apr 30, 2032
Drug: SPK-8011QQ · For: Hemophilia A
Sites: Orange, California; San Francisco, California; Vallejo, California · 6 sites in all
- A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without InhibitorsPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07923981 · 95 participants (planned) · Start Oct 23, 2026 · Primary completion Jul 2, 2029
Drug: marstacimab · For: Hemophilia A or B
Sites: Flowood, Mississippi
SanofiSanofi (SNY)
NCT06941870 · 35 participants (planned) · Start Sep 23, 2025 · Primary completion Oct 25, 2027
Drug: Efanesoctocog alfa · For: Factor VIII Deficiency
Sites: Los Angeles, California; Sacramento, California; Indianapolis, Indiana · 19 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05987449 · 60 participants (planned) · Start Sep 21, 2023 · Primary completion Dec 11, 2033
Drug: NXT007 · For: Hemophilia A
Sites: Sacramento, California; Washington D.C., District of Columbia; Indianapolis, Indiana · 14 sites in all
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia APivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07416604 · 360 participants (planned) · Start Apr 27, 2026 · Primary completion Feb 29, 2028
Drug: Emicizumab · For: Hemophilia A
Sites: Orange, California; Aurora, Colorado; Miami, Florida · 63 sites in all
- A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia APivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07830732 · 84 participants (planned) · Start Oct 16, 2026 · Primary completion Mar 23, 2029
Drug: Denecimig · For: Haemophilia A
Sites: Iowa City, Iowa; Metairie, Louisiana; Minneapolis, Minnesota · 83 sites in all
Arditus Pte LtdIndustry
NCT07787091 · 20 participants (planned) · Start Aug 19, 2026 · Primary completion Mar 2027
Drug: ARD001 · For: Hemophilia A; Healthy Adult Participants
Sites: Singapore, Singapore
- A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07285460 · 85 participants (planned) · Start Dec 18, 2025 · Primary completion Aug 4, 2029
Drug: Fitusiran; Clotting factor concentrates (CFC) or bypassing agents (BPA) and 1 more · For: Hemophilia
Sites: Los Angeles, California; Orange, California; Torrance, California · 37 sites in all
- Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT05145127 · 245 participants (planned) · Start Nov 17, 2021 · Primary completion Jul 31, 2030
Drug: PF-06741086 · For: Hemophilia A; Hemophilia B
Sites: Iowa City, Iowa; New Hyde Park, New York; Philadelphia, Pennsylvania · 78 sites in all
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia APivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07416526 · 138 participants (planned) · Start May 15, 2026 · Primary completion Sep 23, 2027
Drug: Human Coagulation Factor VIII · For: Hemophilia A
Sites: Aurora, Colorado; Iowa City, Iowa; Godoy Cruz, Argentina · 36 sites in all
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06147414 · 550 participants (planned) · Start Oct 23, 2024 · Primary completion May 2027
Drug: Blood sample · For: Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including; Sickle Cell Disease; Cystic Fibrosis and 12 more
Sites: Paris, France
Kiminori Kimura, MDAcademic, hospital or other
NCT07681089 · 7 participants (planned) · Start Oct 1, 2026 · Primary completion Nov 30, 2027
Drug: Foscenvivint · For: Liver Cirrhosis
Sites: Sapporo, Japan; Sendai, Japan; Osaka, Japan · 4 sites in all
University of Texas Southwestern Medical CenterAcademic, hospital or other
NCT07692217 · 60 participants (planned) · Start Jul 22, 2026 · Primary completion May 2033
Drug: Half-life factor VIII based replacement therapy; Non-FVIII based replacement therapy · For: Hemophilia A; Factor VIII (FVIII)
Sites: Dallas, Texas
Emory UniversityAcademic, hospital or other
NCT04023019 · 120 participants (planned) · Start Mar 17, 2020 · Primary completion Dec 2028
Drug: Nuwiq; Octanate and 4 more · For: Hemophilia A
Sites: Atlanta, Georgia; Mörfelden-Walldorf, Germany
SanofiSanofi (SNY)
NCT06145373 · 20 participants (planned) · Start Mar 1, 2024 · Primary completion May 28, 2028
Drug: Fitusiran (SAR439774); Clotting factor concentrates (CFC) or bypassing agents (BPA) and 2 more · For: Hemophilia A
Sites: Los Angeles, California; Flowood, Mississippi; Taipei, Taiwan
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07220564 · 30 participants (planned) · Start Oct 23, 2025 · Primary completion Feb 5, 2027
Drug: NNC0442-0344 A · For: Haemophilia A
Sites: Aurora, Colorado; Indianapolis, Indiana; Iowa City, Iowa · 33 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.